Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness
Not Applicable
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000005848
- Lead Sponsor
- Kyoto university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with contraindiation for the use of the drugs
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method time to progression, time to treatment failure, overall survival, response rate, disease control rate, safety